Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a substantial global disease burden. This study aims to elucidate the role of intestinal NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome in the gut-liver axis and provide novel insights for potential therapeutic targets. Methods Mice were fed with a methionine-choline deficient (MCD) diet for four weeks to induce MASLD models. Nlrp3fl/fl and Vil1creNlrp3fl/fl mice, with a specific knockout of NLRP3 in intestinal epithelial cells, were housed either separately or together to establish models for MASLD. Liver and intestinal tissues were collected for the assessment of hepatic steatosis, inflammation, fibrosis, and integrity of the intestinal mucosal barrier, while fecal microbiota composition was analyzed using 16S rDNA sequencing. The in vivo effects of intragastric butyrate were evaluated using Vil1creNlrp3fl/fl-MCD mice. Results Wild-type (WT)-MCD mice exhibited exacerbated hepatic steatosis and reduced intestinal NLRP3 mRNA expression compared to WT mice fed with a methionine-choline sufficient (MCS) diet, suggesting a protective role of intestinal NLRP3. The Vil1creNlrp3fl/fl-MCD vs. Nlrp3fl/fl-MCD mice exhibited elevated hepatic lipid deposition and increased expression of α-SMA. Additionally, they displayed compromised intestinal mucosal barrier function characterized by shortened villi, reduced goblet cell count, and decreased expression of Reg3a and Cldn7. The co-housed Vil1creNlrp3fl/fl-MCD with Nlrp3fl/fl-MCD mice showed a significantly ameliorated liver phenotype, characterized by reduced steatosis and fibrosis, in comparison with separately-housed Vil1creNlrp3fl/fl-MCD mice. This improvement was accompanied by an increased abundance of Faecalibaculum rodentium, a well-known butyrate producer. The in vivo administration of butyrate significantly ameliorated hepatic lipid accumulation and fibrogenesis in Vil1creNlrp3fl/fl-MCD mice. Further, a significant upregulation of activating protein-1 (AP-1) mRNA levels was observed in the liver of Vil1creNlrp3fl/fl-MCD mice, while both co-housed Vil1creNlrp3fl/fl-MCD mice and butyrate administration significantly exhibited downregulated expression of AP-1. Conclusions Deletion of NLRP3 in intestinal epithelial cells leads to a reduction in the abundance of Faecalibaculum rodentium and butyrate production, resulting in the upregulation of hepatic AP-1 expression, thereby exacerbating MASLD.

NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver disease

Association of NLRP3 inflammasome signaling pathway with progression of chronic obstructive pulmonary disease

Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

NLRP3 Deficiency in Nonimmune Cells Averts Obesity-Induced Fatty Liver Disease

Gut Microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease

NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

NLRP3 inflammasome activation in liver cirrhotic patients

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet

Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases

Effect of High Fat on Expressions of Hepatic NLRP3 Inflammasome-related Genes in vivo and in vitro

Role of NLRP3 Inflammasome Activation in Obesity-Mediated Metabolic Disorders

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice

Impaired Mitophagy Triggers NLRP3 Inflammasome Activation During the Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

NLRP1 is activated by palmitic acid and induced in human metabolic dysfunction-associated steatohepatitis

NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.

Hepatic MCPIP1 protein levels are reduced in NAFLD patients and are predominantly expressed in cholangiocytes and liver endothelium

Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis

Role of NLRP3 inflammasome in liver disease